Dry Eye Disease: Causes, Diagnosis, and Therapies

An estimated 16.4 million adults in the United States have been diagnosed with dry eye disease, with millions more likely experiencing symptoms without a formal diagnosis (National Eye Institute, 2024). Beyond the persistent discomfort — stinging, grittiness, blurred vision that shifts with every blink — the condition can erode quality of life in ways that don't always show up on an eye chart. Reading becomes exhausting. Screen work turns punishing. And the economic burden, including direct medical costs and lost productivity, is substantial enough to have drawn attention from health economists and public health researchers alike.

What Dry Eye Disease Actually Is

The tear film is not just water. It is a three-layered structure: an outer lipid (oil) layer produced by meibomian glands in the eyelids, a middle aqueous (water) layer secreted primarily by the lacrimal glands, and an inner mucin layer from conjunctival goblet cells. Dry eye disease — clinically known as keratoconjunctivitis sicca — occurs when this film becomes unstable, either because the eyes produce insufficient tears or because tears evaporate too quickly.

The Tear Film and Ocular Surface Society's DEWS II report, published in 2017, formally redefined dry eye as a "multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film" accompanied by ocular symptoms and driven by tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities (TFOS DEWS II).

Causes and Risk Factors

Dry eye generally falls into two overlapping categories: aqueous-deficient and evaporative. The evaporative form, often caused by meibomian gland dysfunction, accounts for a larger share of cases — some studies estimate up to 86% of dry eye patients have a significant evaporative component.

Key risk factors include:

• Age. Tear production naturally declines after age 50. Prevalence is roughly double in adults over 75 compared to those aged 18–39 (NEI).
• Sex. Women are affected at significantly higher rates, a disparity linked to hormonal changes during menopause, pregnancy, and oral contraceptive use.
• Medications. Antihistamines, decongestants, antidepressants, and blood pressure medications can all reduce tear secretion. The American Academy of Ophthalmology lists more than 200 systemic medications associated with dry eye (AAO).
• Autoimmune conditions. Sjögren's syndrome, rheumatoid arthritis, and lupus can attack the lacrimal glands directly.
• Environmental factors. Low humidity, wind exposure, air conditioning, and extended digital screen use — which reduces blink rate by as much as 60% — all destabilize the tear film.
• Contact lens wear. Roughly half of contact lens wearers report dry eye symptoms, a figure that has made this one of the leading causes of lens discontinuation.
• Refractive surgery. LASIK temporarily disrupts corneal nerves that regulate tear production. Most patients recover within 6–12 months, though a subset experiences persistent symptoms.

Diagnosis

Diagnosis begins with a thorough history — symptom duration, medication use, systemic health — and validated questionnaires like the Ocular Surface Disease Index (OSDI), a 12-item instrument that scores severity on a 0–100 scale.

Clinical tests include:

• Tear breakup time (TBUT). Fluorescein dye is instilled and the tear film observed under a slit lamp. A breakup time under 10 seconds is generally considered abnormal.
• Schirmer's test. A small strip of filter paper placed inside the lower eyelid measures aqueous tear production over five minutes. Less than 5 mm of wetting suggests aqueous deficiency.
• Ocular surface staining. Fluorescein and lissamine green dyes reveal damaged corneal and conjunctival epithelial cells, respectively.
• Tear osmolarity testing. Devices like the TearLab system measure the salt concentration of tears. Osmolarity above 308 mOsm/L, or a difference greater than 8 mOsm/L between eyes, supports a dry eye diagnosis.
• Meibography. Infrared imaging of the meibomian glands can reveal structural dropout, helping identify the evaporative component.

No single test is definitive. Clinicians typically combine subjective symptom reporting with two or more objective measures.

Therapies

Treatment is stepwise, generally escalating from conservative measures to prescription therapies and procedural interventions.

Foundational Approaches

Artificial tears remain the first line of defense. Preservative-free formulations are preferred for patients using drops more than four times daily, since the preservative benzalkonium chloride (BAK) can itself damage the ocular surface over time. Lipid-based drops may be more effective for patients with meibomian gland dysfunction.

Environmental modifications — humidifiers, screen breaks following the 20-20-20 rule (every 20 minutes, look at something 20 feet away for 20 seconds), and wraparound glasses outdoors — address modifiable triggers.

Prescription Medications

• Cyclosporine ophthalmic emulsion 0.05% (Restasis). FDA-approved in 2003, this calcineurin inhibitor reduces T-cell–mediated inflammation on the ocular surface, increasing tear production over 3–6 months of consistent use (FDA).
• Lifitegrast 5% (Xiidra). Approved by the FDA in 2016, this lymphocyte function-associated antigen-1 (LFA-1) antagonist blocks a specific inflammatory pathway. Clinical trials showed significant improvement in eye dryness scores within 12 weeks.
• Varenicline nasal spray (Tyrvaya). Approved in 2021, this nicotinic acetylcholine receptor agonist stimulates tear production via the trigeminal parasympathetic pathway — a mechanistically distinct approach delivered through the nose rather than the eye.
• Short-course topical corticosteroids. Used to break acute inflammatory flares, though long-term use carries risks of elevated intraocular pressure and cataract formation.

Procedural and Device-Based Options

• Punctal plugs. Tiny silicone or collagen plugs inserted into the tear drainage ducts retain tears on the ocular surface longer.
• Thermal pulsation (LipiFlow). This in-office device applies controlled heat and pressure to the inner eyelids, clearing obstructed meibomian glands. A randomized trial published in Clinical Ophthalmology demonstrated sustained improvement in gland function at 12 months.
• Intense pulsed light (IPL). Originally a dermatological tool, IPL applied to the periorbital skin reduces inflammation and abnormal blood vessels contributing to meibomian gland dysfunction.
• Amniotic membrane therapy. Cryopreserved amniotic membranes placed on the ocular surface promote healing in moderate-to-severe cases resistant to conventional treatment.

Living With Dry Eye

Dry eye disease is chronic for most patients, not a condition that resolves with a single prescription. The practical reality is management, not cure — a combination of therapies adjusted over time based on symptom response and clinical findings. Patients who understand the multifactorial nature of the disease tend to adhere better to treatment plans and experience more consistent relief.

Research into novel therapies, including gene-based approaches and next-generation anti-inflammatory agents, continues to expand the treatment landscape. The condition may be common, but it is far from simple — and taking it seriously is the first step toward meaningful relief.

References

• National Eye Institute — Dry Eye
• TFOS DEWS II Report
• American Academy of Ophthalmology — Dry Eye
• FDA — Restasis Prescribing Information
• National Library of Medicine — Dry Eye Disease Overview

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)